An epidemiological profile of chronic obstructive pulmonary disease

Sinha, Bireshwar; Vibha,; Singla, Rupak; Chowdhury, Ranadip

doi:10.4103/0022-3859.194200

Cited by 34 publications

(32 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study also indentified the prevalence among Bidi (filled with crude tobacco flake and mainly wrapped in a Piliostigma racemosum leaf) and cigarette smokers was 8.2 and 5.9%, respectively (Jindal et al, 2006 ). A recent cross sectional study was conducted among twelve hundred adults in Delhi, India (Sinha et al, 2017 ). This study suggested the prevalence of COPD was 10%, and the tobacco smoking adults were the strongest risk factor with this disease.…”

Section: Indian Prospectivementioning

confidence: 99%

“…This study suggested the prevalence of COPD was 10%, and the tobacco smoking adults were the strongest risk factor with this disease. The old smoker had 63 % lesser risk as compare to current smokers (Sinha et al, 2017 ). Further, environmental smoke, occupational exposure, age factor, and biomass fuel are the others important factors which influence this health problem (Sinha et al, 2017 ).…”

Section: Indian Prospectivementioning

confidence: 99%

“…The old smoker had 63 % lesser risk as compare to current smokers (Sinha et al, 2017 ). Further, environmental smoke, occupational exposure, age factor, and biomass fuel are the others important factors which influence this health problem (Sinha et al, 2017 ). Due to heterogeneity, limited numbers of studies and further their unsuitability for meta-analysis, these discussed figures are most unlikely to apply for all subpopulations in India.…”

Section: Indian Prospectivementioning

confidence: 99%

See 2 more Smart Citations

Role of Proteases in Chronic Obstructive Pulmonary Disease

Pandey¹,

Mishra

2017

Front. Pharmacol.

113

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is generally associated with progressive destruction of airways and lung parenchyma. Various factors play an important role in the development and progression of COPD, like imbalance of proteases, environmental and genetic factors and oxidative stress. This review is specifically focused on the role of proteases and their imbalance in COPD. There are three classes (serine, mettalo, and cysteine) of proteases involved in COPD. In serine proteases, neutrophil elastase, cathepsin G, and proteinase-3 are involved in destruction of alveolar tissue. Matrix-mettaloproteinase-9, 12, 13, plays an influential role in severity of COPD. Among cysteine proteases, caspase-3, caspases-8 and caspase-9 play an important role in controlling apoptosis. These proteases activities can be regulated by inhibitors like α-1-antitrypsin, neutrophil elastase inhibitor, and leukocyte protease inhibitor. Studies suggest that neutrophil elastase may be a therapeutic target for COPD, and specific inhibitor against this enzyme has potential role to control the disease. Current study suggests that Dipeptidyl Peptidase IV is a potential marker for COPD. Since the expression of proteases and its inhibitors play an important role in COPD pathogenesis, therefore, it is worth investigating the role of proteases and their regulation. Understanding the biochemical basis of COPD pathogenesis using advanced tools in protease biochemistry and aiming toward translational research from bench-to-bedside will have great impact to deal with this health problem.

show abstract

Section: Indian Prospectivementioning

confidence: 99%

Section: Indian Prospectivementioning

confidence: 99%

Section: Indian Prospectivementioning

confidence: 99%

See 1 more Smart Citation

Role of Proteases in Chronic Obstructive Pulmonary Disease

Pandey¹,

Mishra

2017

Front. Pharmacol.

113

View full text Add to dashboard Cite

show abstract

“…This distribution can be explained by the physiological decrease in FEV1 with age where the slope becomes steeper when aggravated by risk factors, particularly smoking. 5 The mean duration of COPD was 9.49±7.199 years.…”

Section: Discussionmentioning

confidence: 97%

“…3 In India, the prevalence of COPD has been reported at 3.49% (ranging from 1.1% in Mumbai to 10% in Thiruvananthapuram). 4,5 Bronchodilators continue to be the keystone of pharmacological treatment in patients with COPD. For the management of stable COPD; long-acting β 2 -agonists (LABA) and long-acting muscarinic antagonists (LAMA) are often preferred.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and tolerability of formoterol plus glycopyrronium combination in patients with chronic obstructive pulmonary disease: FINE registry

Gopal¹,

Garde

et al. 2020

Int J Adv Med

View full text Add to dashboard Cite

Background: Long-term therapy for chronic obstructive pulmonary disease (COPD) is progressing fast. Dual bronchodilation with long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) fixed dose combinations (FDC) have been available over the past few years. To evaluate the real-world tolerability and effectiveness of formoterol plus glycopyrronium FDC inhaler, a post-marketing surveillance study was conducted in Indian population.Methods: This was an open-label, observational registry in which COPD patients, who were prescribed forglyn (a brand of FDC of glycopyrronium 25 mcg and formoterol fumarate dihydrate 6 mcg dry powder inhalation). The effectiveness, safety and tolerability of this LAMA/LABA combination were evaluated for 4, 8 and 12 weeks. The safety and tolerability was assessed based on the incidence of adverse events (AEs). Effectiveness was evaluated based on change in total symptom score from baseline to end of 12 weeks. The forced expiratory volume in 1 second (FEV1) was performed at baseline and end of 12 weeks.Results: Total COPD patients enrolled were 605, of which 78.5% were males and 21.5% were females. Patients showing improvement of symptoms at week 4 were 587 (97.02%).Overall, at the end of 8 week and 12 week 98.34 % and 99.49% patients showed improvement in the total symptoms respectively. About 0.49% did not show any improvement. AEs were reported in 64 (10.64%) patients with no serious AEs. Mean FEV1 of 476 patients before treatment was 1.53±0.68 L at baseline which changed to 1.85±4.74 L at the end of 12 weeks, with was statistically significant (p<0.05).Conclusions: In real-life clinical practice in India, formoterol and glycopyrronium FDC dry powder inhaler was well tolerated in COPD patients, and can be regarded as an effective option for maintenance treatment.

show abstract